Seladelpar
Seladelpar (INN, USAN; developmental code names MBX-8025, RWJ-800025) is a PPARδ receptor agonist that is being investigated for drug use by Metabolex.[1][2][3] According to a press release they are examining its potential use for the treatment of dyslipidemia, metabolic syndrome, type 2 diabetes, and non-alcoholic steatohepatitis (NASH). The compound was licensed from Janssen Pharmaceutica NV.[4]
 | |
| Clinical data | |
|---|---|
| Other names | MBX-8025; RWJ-800025 |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C21H23F3O5S |
| Molar mass | 444.47 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
References
- "Seladelpar - CymaBay Therapeutics - AdisInsight".
- Billin, A. N. (2008). "PPAR-β/δ agonists for Type 2 diabetes and dyslipidemia: An adopted orphan still looking for a home". Expert Opinion on Investigational Drugs. 17 (10): 1465–1471. doi:10.1517/13543784.17.10.1465. PMID 18808307.
- Bays HE, Schwartz S, Littlejohn T, Kerzner B, Krauss RM, Karpf DB, Choi YJ, Wang X, Naim S, Roberts BK (September 2011). "MBX-8025, a novel peroxisome proliferator receptor-delta agonist: lipid and other metabolic effects in dyslipidemic overweight patients treated with and without atorvastatin". J. Clin. Endocrinol. Metab. 96 (9): 2889–97. doi:10.1210/jc.2011-1061. PMID 21752880.
- "Targeting Mixed Dyslipidemia and Metabolic Syndrome". Archived from the original on 2006-10-17.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.